34703399|t|Metabolic positron-emission tomography/magnetic resonance imaging in primary progressive aphasia and frontotemporal lobar degeneration subtypes: Reassessment of expected [18F]-fluorodeoxyglucose uptake patterns.
34703399|a|Clinical assessment of frontotemporal lobar degeneration (FTLD)/primary progressive aphasia (PPA) patients is challenging, given that common cognitive assessments rely extensively on language. Since asymmetry in neuroimaging biomarkers is often described as a central finding in these patients, our study evaluated [18F]-fluorodeoxyglucose (FDG) uptake patterns in patients meeting clinical and imaging criteria for FTLD, with emphasis on PPA. Fifty-one subjects underwent brain [18F]-FDG positron-emission tomography/magnetic resonance imaging (PET/MRI) as part of their routine clinical workup for dementia and neurodegenerative disease. Images were obtained using a Siemens Biograph mMR integrated 3T PET/MRI scanner. PET surface maps and fusion fluid-attenuated inversion recovery-PET images were generated utilizing MIMneuro software. Two board-certified neuroradiologists and one nuclear medicine physician blinded to patient history classified each FTLD/PPA subtype and assessed for left- versus right-side dominant hypometabolism. Qualitative and semiquantitative assessment demonstrated 18 cases of PPA, 16 behavioral variant frontotemporal dementia (bvFTD), 12 corticobasal degeneration, and 5 progressive supranuclear palsy. Among the 18 PPA subjects (11 svPPA, 5 lvPPA, and 2 agPPA), 12 (67%) demonstrated left-dominant hypometabolism and 6 (33%) right-dominant hypometabolism. While existing literature stresses left-dominant hypometabolism as a key imaging feature in the PPA subtypes, a third of our cases demonstrated right-dominant hypometabolism, suggesting that emphasis should be placed on the functionality of specific brain regions affected, rather than left versus right sidedness of hypometabolism patterns.
34703399	69	96	primary progressive aphasia	Disease	MESH:D018888
34703399	101	134	frontotemporal lobar degeneration	Disease	MESH:D057174
34703399	170	194	[18F]-fluorodeoxyglucose	Chemical	MESH:D019788
34703399	235	268	frontotemporal lobar degeneration	Disease	MESH:D057174
34703399	270	274	FTLD	Disease	MESH:D057174
34703399	276	303	primary progressive aphasia	Disease	MESH:D018888
34703399	305	308	PPA	Disease	MESH:D018888
34703399	310	318	patients	Species	9606
34703399	497	505	patients	Species	9606
34703399	527	551	[18F]-fluorodeoxyglucose	Chemical	MESH:D019788
34703399	553	556	FDG	Chemical	MESH:D019788
34703399	577	585	patients	Species	9606
34703399	628	632	FTLD	Disease	MESH:D057174
34703399	651	654	PPA	Disease	MESH:D018888
34703399	691	700	[18F]-FDG	Chemical	MESH:D019788
34703399	812	820	dementia	Disease	MESH:D003704
34703399	825	850	neurodegenerative disease	Disease	MESH:D019636
34703399	1136	1143	patient	Species	9606
34703399	1168	1172	FTLD	Disease	MESH:D057174
34703399	1173	1176	PPA	Disease	MESH:D018888
34703399	1235	1249	hypometabolism	Disease	
34703399	1320	1323	PPA	Disease	MESH:D018888
34703399	1328	1370	behavioral variant frontotemporal dementia	Disease	MESH:D057180
34703399	1372	1377	bvFTD	Disease	MESH:D057180
34703399	1383	1408	corticobasal degeneration	Disease	MESH:D000088282
34703399	1416	1446	progressive supranuclear palsy	Disease	MESH:D013494
34703399	1461	1464	PPA	Disease	MESH:D018888
34703399	1478	1483	svPPA	Disease	
34703399	1487	1492	lvPPA	Disease	
34703399	1500	1505	agPPA	Disease	
34703399	1544	1558	hypometabolism	Disease	
34703399	1586	1600	hypometabolism	Disease	
34703399	1651	1665	hypometabolism	Disease	
34703399	1698	1701	PPA	Disease	MESH:D018888
34703399	1761	1775	hypometabolism	Disease	
34703399	1919	1933	hypometabolism	Disease	
34703399	Association	MESH:D019788	MESH:D003704
34703399	Association	MESH:D019788	MESH:D019636
34703399	Association	MESH:D019788	MESH:D057174

